---
reference_id: "PMID:39199267"
title: A Multi-Target Pharmacological Correction of a Lipoyltransferase LIPT1 Gene Mutation in Patient-Derived Cellular Models.
authors:
- Gómez-Fernández D
- Romero-González A
- Suárez-Rivero JM
- Cilleros-Holgado P
- Álvarez-Córdoba M
- Piñero-Pérez R
- Romero-Domínguez JM
- Reche-López D
- López-Cabrera A
- Ibáñez-Mico S
- Castro de Oliveira M
- Rodríguez-Sacristán A
- González-Granero S
- García-Verdugo JM
- Sánchez-Alcázar JA
journal: Antioxidants (Basel)
year: '2024'
doi: 10.3390/antiox13081023
content_type: abstract_only
---

# A Multi-Target Pharmacological Correction of a Lipoyltransferase LIPT1 Gene Mutation in Patient-Derived Cellular Models.
**Authors:** Gómez-Fernández D, Romero-González A, Suárez-Rivero JM, Cilleros-Holgado P, Álvarez-Córdoba M, Piñero-Pérez R, Romero-Domínguez JM, Reche-López D, López-Cabrera A, Ibáñez-Mico S, Castro de Oliveira M, Rodríguez-Sacristán A, González-Granero S, García-Verdugo JM, Sánchez-Alcázar JA
**Journal:** Antioxidants (Basel) (2024)
**DOI:** [10.3390/antiox13081023](https://doi.org/10.3390/antiox13081023)

## Content

1. Antioxidants (Basel). 2024 Aug 22;13(8):1023. doi: 10.3390/antiox13081023.

A Multi-Target Pharmacological Correction of a Lipoyltransferase LIPT1 Gene 
Mutation in Patient-Derived Cellular Models.

Gómez-Fernández D(1), Romero-González A(1), Suárez-Rivero JM(1), 
Cilleros-Holgado P(1), Álvarez-Córdoba M(1), Piñero-Pérez R(1), Romero-Domínguez 
JM(1), Reche-López D(1), López-Cabrera A(1), Ibáñez-Mico S(2), Castro de 
Oliveira M(3)(4)(5), Rodríguez-Sacristán A(5)(6), González-Granero S(7), 
García-Verdugo JM(7), Sánchez-Alcázar JA(1).

Author information:
(1)Centro Andaluz de Biología del Desarrollo (CABD-CSIC-Universidad Pablo de 
Olavide), 41013 Sevilla, Spain.
(2)Hospital Clínico Universitario Virgen de la Arrixaca, Servicio de 
Neuropediatría, 30120 Murcia, Spain.
(3)Neuropediatria, Neurolinkia, C. Jardín de la Isla, 8, Local 4 y 5, 41014 
Sevilla, Spain.
(4)FEA Pediatría, Centro Universitario Hospitalar de Faro, R. Leão Penedo, 
8000-386 Faro, Portugal.
(5)Neuropediatria, Servicio de Pediatría, Hospital Universitario Virgen 
Macarena, 41009 Sevilla, Spain.
(6)Departamento de Farmacología, Radiología y Pediatría de la Facultad de 
Medicina de la Universidad de Sevilla, 41009 Sevilla, Spain.
(7)Laboratory of Comparative Neurobiology, Cavanilles Institute of Biodiversity 
and Evolutionary Biology, University of Valencia and CIBERNED-ISCIII, 46980 
Valencia, Spain.

Mutations in the lipoyltransferase 1 (LIPT1) gene are rare inborn errors of 
metabolism leading to a fatal condition characterized by lipoylation defects of 
the 2-ketoacid dehydrogenase complexes causing early-onset seizures, psychomotor 
retardation, abnormal muscle tone, severe lactic acidosis, and increased urine 
lactate, ketoglutarate, and 2-oxoacid levels. In this article, we characterized 
the disease pathophysiology using fibroblasts and induced neurons derived from a 
patient bearing a compound heterozygous mutation in LIPT1. A Western blot 
analysis revealed a reduced expression of LIPT1 and absent expression of 
lipoylated pyruvate dehydrogenase E2 (PDH E2) and alpha-ketoglutarate 
dehydrogenase E2 (α-KGDH E2) subunits. Accordingly, activities of PDH and α-KGDH 
were markedly reduced, associated with cell bioenergetics failure, iron 
accumulation, and lipid peroxidation. In addition, using a pharmacological 
screening, we identified a cocktail of antioxidants and mitochondrial boosting 
agents consisting of pantothenate, nicotinamide, vitamin E, thiamine, biotin, 
and α-lipoic acid, which is capable of rescuing LIPT1 pathophysiology, 
increasing the LIPT1 expression and lipoylation of mitochondrial proteins, 
improving cell bioenergetics, and eliminating iron overload and lipid 
peroxidation. Furthermore, our data suggest that the beneficial effect of the 
treatment is mainly mediated by SIRT3 activation. In conclusion, we have 
identified a promising therapeutic approach for correcting LIPT1 mutations.

DOI: 10.3390/antiox13081023
PMCID: PMC11351668
PMID: 39199267

Conflict of interest statement: We declare no conflicts of interest.